(AMGN) - Analyzing Amgen's Short Interest

Benzinga50minutes ago

Roche Sees Carmot Obesity Drugs' Potential Peak Sales at $3.6B+: Report

Seeking AlphaSep 30 23:25

Amgen Inc. (AMGN): Hedge Fund Interest and Strong Pipeline Support Moderate Buy Rating

Yahoo FinanceSep 30 17:02

Novo Nordisk's Ozempic, Regeneron/Sanofi's Dupixent Set to Advance in Top Drug Sales

Seeking AlphaSep 30 00:12

Institutional Investors May Overlook Amgen Inc.'s (NASDAQ:AMGN) Recent US$7.9b Market Cap Drop as Long-term Gains Remain Positive

Yahoo FinanceSep 29 19:01

Here Are the Medicare Part D Drugs Expected to Face 2025 Price Negotiations

Seeking AlphaSep 29 01:06